“We are delighted to provide doctors now with improved fundus cameras
that support fast and reliable diagnosis and follow-up of challenging
retinal eye diseases like dry AMD, glaucoma and diabetic retinopathy
through brilliant pictures that offer more details,” says Dr. Ludwin
Monz, Chief Executive Officer of Carl Zeiss Meditec AG. “The new Fundus
Cameras are part of our comprehensive retinal and glaucoma solution
that, combined with the CIRRUS HD-OCT, provide doctors with complete
information on the retina and optic disc.”
Backed by an internal 24 MP sensor, a newly designed optical system and
enhanced post-processing for fast and informative imaging, the fundus
cameras produce unprecedented image quality from a non mydriatic design.
At the same time, the system is easy to use. Both new VISUCAM models
include Fundus Autofluorescence (FAF) as a standard feature to support
current and emerging therapeutic management options for dry AMD. Other
standard modalities such as color and red-free enhance the visualization
of different anatomical features. Thanks to superior image quality,
pictures taken by the new cameras also facilitate patient education.
The new VISUCAM 524 will also offer Fluorescein Angiography and optional
Indocyanine Green Angiography for the assessment of vascular blood flow
and leakage.
VISUCAM 224 / 524 is available in the US, Canada, the European Union and
throughout Asia.
The portable fundus camera VISUSCOUT® 100
for retinal examinations
Also part of the ophthalmic portfolio of ZEISS is the mobile fundus
camera VISUSCOUT® 100. This especially light and compact
device, designed to bring retina imaging to smaller practices and mobile
ophthalmic stations, is equipped with strong batteries for mobile use.
It is part of the Essential Line of ZEISS and was recently awarded a Red
Dot award for good product design.
ZEISS has a long tradition in advancing technology to examine the back
of the eye: In 1926 Johan Nordenson and ZEISS made the first modern
fundus camera commercially available for use by practitioners and the
first fluorescein angiography (FFA) in 1959 was performed using a ZEISS
fundus camera.
Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX
of the German stock exchange, is one of the world’s leading medical
technology companies. The Company supplies innovative technologies and
application-oriented solutions designed to help doctors improve the
quality of life of their patients. It provides complete packages of
solutions for the diagnosis and treatment of eye diseases, including
implants and consumable materials. The Company creates innovative
visualization solutions in the field of microsurgery. The medical
technology portfolio of ZEISS is rounded off by promising future
technologies such as intraoperative radiation therapy. With almost 3,000
employees worldwide, the Group generated revenue of € 909 million in
financial year 2013/2014 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has
subsidiaries in Germany and abroad; more than 50 percent of its
employees are based in the USA, Japan, Spain and France. The Center for
Application and Research (CARIn) in Bangalore, India and the Carl Zeiss
Innovations Center for Research and Development in Shanghai, China,
strengthen the Company’s presence in these rapidly developing economies.
Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float.
The remaining approx. 65 percent are held by Carl Zeiss AG, one of the
world’s leading companies in the optical and optoelectronic industries.
For more information visit our website at: www.zeiss.com/med
Copyright (2015) Business Wire.
All Rights Reserved.
Article source